Chordia Therapeutics (TSE:190A) Change In Receivables : 円0.00 Mil (TTM As of Aug. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Chordia Therapeutics Change In Receivables?

Chordia Therapeutics's change in receivables for the quarter that ended in Aug. 2024 was 円0.00 Mil. It means Chordia Therapeutics's Accounts Receivable stayed the same from Aug. 2023 to Aug. 2024 .

Chordia Therapeutics's change in receivables for the fiscal year that ended in Aug. 2024 was 円0.00 Mil. It means Chordia Therapeutics's Accounts Receivable stayed the same from Aug. 2023 to Aug. 2024 .

Chordia Therapeutics's Accounts Receivable for the quarter that ended in Aug. 2024 was 円0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Chordia Therapeutics's liquidation value for the three months ended in Aug. 2024 was 円3,858.55 Mil.

Chordia Therapeutics Change In Receivables Historical Data

The historical data trend for Chordia Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chordia Therapeutics Change In Receivables Chart

Chordia Therapeutics Annual Data

Trend

Aug21

Aug22

Aug23

Aug24

Change In Receivables

Chordia Therapeutics Quarterly Data
	Aug21	Aug22	Aug23	Aug24
Change In Receivables	-	-	-	-

Chordia Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Aug. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.00 Mil.

Chordia Therapeutics (TSE:190A) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Chordia Therapeutics's Days Sales Outstanding for the quarter that ended in Aug. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Chordia Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Chordia Therapeutics's liquidation value for the quarter that ended in Aug. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	4329.624	-	471.073	+	0.75 * 0	+	0.5 * 0
=	3,858.55

Chordia Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Chordia Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Chordia Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chordia Therapeutics Inc (TSE:190A) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

2-26-1 Muraoka-Higashi, Kanagawa, Fujisawa, JPN, 251-0012

Website

https://www.chordiatherapeutics.com

Chordia Therapeutics Inc is a bio-venture company specializing in cancer research and development. Its mission is to deliver first-in-class cancer drugs to patients. It is a clinical-stage biotech company engaged in researching and developing novel therapies for cancers with high unmet medical needs.

Chordia Therapeutics Headlines

No Headlines